Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients
10.3969/j.issn.1006-0111.2015.03.018
- VernacularTitle:吉西他滨对胰腺癌外周血调节性T细胞影响的研究
- Author:
Xiaoxia KOU
1
;
Yongmei DING
;
Yao HUANG
;
Zhengang YUAN
;
Qijun QIAN
Author Information
1. 东方肝胆外科医院生物治疗科
- Keywords:
gemcitabine;
pancreatic cancer;
regulatory T cells(Tregs);
adoptive immunotherapy
- From:
Journal of Pharmaceutical Practice
2015;(3):258-260,268
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the influence of gemcitabine chemotherapy on levels of regulatory Tcells (Tregs) in peripheral blood for patients with pancreatic cancer and provide evidence and reference for improving the efficacy of adoptive im-munotherapy .Methods 32 patients were enrolled in this study from January 2012 to October 2014 ,among whom 16 received gemcitabine chemotherapy combined with adoptive immunotherapy (gemcitabine group) ,the other 16 patients received adoptive immunotherapy only(control group) .The level of Tregs in peripheral blood ,side effect and overall survival were observed be-fore and after the therapy .Results The number of Tregs in peripheral blood was significantly decreased after gemcitabine chemotherapy ,and it was also lower than that of the control group .The overall survival time of the gemcitabine group was 1.3 mo longer than the control group(10 .0 mo vs 8 .7 mo) .Conclusion Therapeutic regimen of gemcitabine can remarkly de-plete Tregs in peripheral blood of patients with pancreatic cancer ,effectively regulate tumor immune tolerance ,and improve the efficacy of adoptive immunotherapy .
